Clinical trial
Study MEA117113: Mepolizumab vs. Placebo as Add-on Treatment for Frequently Exacerbating COPD Patients Characterized by Eosinophil Level
NCT02105961 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Study MEA117113: Mepolizumab vs. Placebo as Add-on Treatment for Frequently Exacerbating COPD Patients Characterized by Eosinophil Level
- Lead sponsor
- GlaxoSmithKline
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- April 24, 2014
- Completion date
- January 16, 2017
- Enrollment
- 674 (actual)
- Sites
- 169
Conditions
As the registry lists them; a condition with its own page is linked.